New Insights into the Pathogenesis of Depression: A Review of Purinergic Signaling

Strategic Insights -

Purinergic signaling has emerged as a critical pathway in the development of major depressive disorder (MDD). Researchers at the Chengdu University of Traditional Chinese Medicine have conducted a comprehensive review of the evidence, highlighting the role of adenosine 5'-triphosphate (ATP), adenosine, and their P2/P1 receptor-mediated purinergic signaling in the pathogenesis of depression. The study reveals that extracellular ATP and adenosine play a significant role in regulating neuroinflammation and synaptic plasticity, leading to depressive-like behavior.

Key Takeaways:

  • Major depressive disorder (MDD) is a mental illness characterized primarily by persistent low mood and anhedonia.
  • Traditional monoamine antidepressants have not achieved entirely satisfactory clinical efficacy.
  • Recent studies have revealed that extracellular ATP, adenosine, and their P2/P1 receptor-mediated purinergic signaling play a significant role in the pathogenesis of depression.
  • The review highlights the distinct roles of the purinergic ionotropic P2XRs (especially P2X7) and metabotropic P2YRs in regulating neuroinflammation and synaptic plasticity.
  • Adenosine metabolic imbalance and altered function of adenosine A1 and A2ARs further promote pathological processes in depression.
  • Intervention strategies targeting different purinergic pathways, including P2X7R antagonists, adenosine receptor modulators, and S-adenosylmethionine (SAMe), have been outlined.
  • Researchers have pointed out outstanding challenges for the translation of these strategies towards a clinical application.
  • The study has been peer-reviewed and published in the journal Pharmacological Research.

Statistics:

  • 107989 is the article number for the study published in Pharmacological Research.
  • The journal Pharmacological Research is published by Academic Press Ltd- Elsevier Science Ltd, with an international office in London (England).
  • The study has been conducted by researchers at the Chengdu University of Traditional Chinese Medicine, led by Patrizia Rubini and Xing-Ying Ren.
  • The additional authors on the study include Tobias Engel, Yong Tang, and Peter Illes.

Sources:

  • Purinergic modulation of major depressive disorder: experimental findings, pathogenesis and therapeutic opportunities. Pharmacological Research, 2025:107989.
  • PharmAcademic Press Ltd- Elsevier Science Ltd, 24-28 Oval Rd, London NW1 7DX, England. (Elsevier - www.elsevier.com; Pharmacological Research - www.journals.elsevier.com/pharmacological-research/)
  • Mental Health Weekly Digest, October 20, 2025; p 253.